Sana Karam, MD, PhD

Tumor Immunology, TME, Systemic Immunity, Radiation Oncology, Wash U

[Sana Karam, MD, PhD @KaramLab]

@DavidSherMD @EbnerMD Amen to that! This is worth getting to SOC. All we need is a blood biomarker or something other than FMISO so it can be applied widely @xrtGenomics , hurry up and come up with it! 🙃

[WashU Medicine Radiation Oncology @WashUMedRadOnc]

It's #ClinicalTrialsDay and we are grateful to our team who help connect treatments to the patients who need them.
#CTD2026 #ResearchRising

[Sana Karam, MD, PhD @KaramLab]

@Atem84 @igzalina @OncoAlert Those numbers at risk are way too small to derive any meaningful conclusions from these data. The arms are so imbalanced to begin with. But let’s hope 🤞🏽

[Sana Karam, MD, PhD @KaramLab]

@adib_elio Conventionally fractionated chemoradiation. It’s imperative that such specification be included.

[CU Anschutz Cancer Center @CUCancerCenter]

The Tumor-Host Interactions program, led by Diana Cittelly, PhD, explores how the body shapes cancer, advancing immunotherapies for better patient outcomes.

Watch the full interview here: https://t.co/pL1WqSFi83

[Sana Karam, MD, PhD @KaramLab]

@Nature Will have to read it in detail, but how is this even a delta? The difference is barely there. Just because a p value is <0.05 doesn’t necessarily render the response meaningful.

[NRG Oncology @NRGonc]

NRG-HN016 CONCISE is a pragmatic Phase 3 trial for cisplatin-ineligible locoregionally advanced #headandneckcancer. It is anticipated to be activating soon. Study PI, Dr. Loren Mell @drlorenmell describes the design of the trial in our April newsletter: https://t.co/q1m4ggSexW

[WashU Medicine Radiation Oncology @WashUMedRadOnc]

So thrilled to celebrate our @washumedicine Dean's Impact awards winners! 🎉Jiayi Huang, MD, MSCI & Thomas Mazur, PhD were recognized for their outstanding efforts to improve clinical care, education & research. https://t.co/QWwYVh9wm0

[NRG Oncology @NRGonc]

We are pleased to highlight NRG-CC017 in our April newsletter. This trial is the 1st ever NRG GBM trial with a focus on symptom prevention. We also would like to thank @djlee714 & @AlexisNarvaezMD for talking w/CC017 study PI, Dr. Huang at #NRG2026: https://t.co/BZrGTlZ1fs.

[WashU Medicine Radiation Oncology @WashUMedRadOnc]

Physician-scientist @CarlDeSelm presented his research findings at #AACR26!
"A novel, first in class chimeric antigen receptor dendritic cell platform driving broad and durable antitumor immunity in solid tumors"
#immunotherapy #CancerResearch

[WashU Medicine Radiation Oncology @WashUMedRadOnc]

Multiple @SitemanCenter @washumedicine experts will be recognized and presenting at #AACR26 over the next week.
#Radonc @CarlDeSelm presents in the Mon April 20 Adoptive T Cell Therapy Session! Links here-
https://t.co/q7eIQr9Rl4
#Immunotherapy

[Eric Topol @EricTopol]

The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging
https://t.co/GjcuZ8luNM

[UW-Madison Department of Human Oncology @UWMadisonRadMed]

📣 Student Shoutout! ⭐
Sophie Bice recently matched into the Radiation Oncology residency program at Washington University, where she will have ample opportunity to continue amazing research. We are all very proud of her and so excited to see all that she will accomplish!

[NRG Oncology @NRGonc]

Protocol Activation! NRG-CC017: A randomized phase III study comparing temporally-modulated pulsed radiation therapy (TMPRT) versus standard radiation therapy with temozolomide for adults with newly diagnosed MGMT-unmethylated glioblastoma https://t.co/OufdYFBx0F

[Sana Karam, MD, PhD @KaramLab]

@xrtcell @safaviaa @CD_AACR Congrats, Anusha and @JieDengMDPhD . Very nice story and kudos on doing the translational work .

[Sana Karam, MD, PhD @KaramLab]

@Nature I hope AI Scientist will remember that there are trainees who spend years on end generating these data when nitpicking on some random things that have no bearing whatsoever on anything. In that sense, it maybe more merciful and less destructive than humans..

[UCLA Jonsson Comprehensive Cancer Center @UCLAHealthJCCC]

A new study co-led by UCLA & published in the journal @CD_AACR suggests combining targeted radiation therapy with an experimental immune-boosting drug & anti-PD-1 therapy before surgery may help the immune system fight aggressive soft tissue sarcomas.
https://t.co/kgUVwftmti

[Sana Karam, MD, PhD @KaramLab]

@DrChoueiri @NEJM @MRCCTU @DanaFarber @neerajaiims @bergsa83 @MikeSerzanMD @PCF_Science @PCFnews @ZEROCancer @PrafulRavi1 @AtishChoudhury @Prof_Nick_James About time!

[Toni Choueiri, MD @DrChoueiri]

We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability. Not new—just better applied. Study in @NEJM by the #Stampede group/@MRCCTU

https://t.co/Pq17ahdPgu

[Penn Otorhinolaryngology @Penn_ENT]

Now published: New study on the controversial role of confirmatory HPV testing in p16+ OPCs 📚
Corresponding author: @BasuLab1
Read more: https://t.co/XVto8rtm9v link in our bio 🔗
#AcademicMedicine #Research #HPV #headandneckcancer